GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (FRA:1E6) » Definitions » Institutional Ownership

Eagle Pharmaceuticals (FRA:1E6) Institutional Ownership : 24.71% (As of Jun. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eagle Pharmaceuticals's institutional ownership is 24.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eagle Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eagle Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 64.50%.


Eagle Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Eagle Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Institutional Ownership Chart

Eagle Pharmaceuticals Historical Data

The historical data trend for Eagle Pharmaceuticals can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 52.64 53.66 52.83 50.55 49.67 40.23 37.22 30.82 25.02 24.71

Eagle Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Eagle Pharmaceuticals (FRA:1E6) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals (FRA:1E6) Headlines

No Headlines